For decades, the textbook view held that inflammation simply faded out — a passive dilution as pro-inflammatory mediators got cleared. Then Charles Serhan’s lab at Harvard demonstrated something different: the body actively turns inflammation off using a distinct class of lipid mediators biosynthesized from EPA and DHA. These molecules — resolvins, protectins, and maresins — bind specific G-protein coupled receptors and orchestrate the cellular choreography of resolution. The implication is profound: omega-3 fatty acids aren’t merely anti-inflammatory. They’re the substrate for a dedicated resolution program.
What Are Specialized Pro-Resolving Mediators?
Specialized pro-resolving mediators (SPMs) are endogenous lipid signaling molecules enzymatically derived from omega-3 polyunsaturated fatty acids — primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with a smaller contribution from n-3 docosapentaenoic acid (n-3 DPA) and arachidonic acid (which yields lipoxins). The major SPM families include the E-series resolvins (RvE1-RvE3) derived from EPA; the D-series resolvins (RvD1-RvD6), protectins (PD1/NPD1), and maresins (MaR1, MaR2) derived from DHA; and the lipoxins (LXA4, LXB4) derived from arachidonic acid.[1]
The biosynthetic enzymes — predominantly 15-lipoxygenase, 5-lipoxygenase, and aspirin-acetylated COX-2 — convert these fatty acid precursors into stereochemically specific compounds at picomolar to nanomolar concentrations. Unlike traditional anti-inflammatory drugs that block prostaglandin or leukotriene synthesis, SPMs do not suppress the initiation of inflammation. They actively program its termination.[2]
How SPMs Work
Receptor-Mediated Signaling: SPMs act through specific G-protein coupled receptors rather than diffuse membrane effects. Resolvin E1 binds ChemR23 (also called ERV1) and antagonizes BLT1, the leukotriene B4 receptor. Resolvin D1 signals through ALX/FPR2 and GPR32. Maresin 1 acts via LGR6. This receptor specificity explains why SPMs operate at sub-nanomolar concentrations — they are not bulk membrane modulators but high-affinity ligands.[2]
Neutrophil Cessation and Macrophage Repolarization: Once inflammation has neutralized a pathogen or insult, SPMs halt further neutrophil infiltration into tissue and stimulate non-phlogistic recruitment of monocytes that differentiate into pro-resolving macrophages. These macrophages efferocytose — meaning they engulf — apoptotic neutrophils, clearing the cellular debris that would otherwise propagate damage.[3]
Class Switch in Lipid Mediators: During acute inflammation, there is a temporal shift in which a single inflammatory locus first produces prostaglandins and leukotrienes, then switches to lipoxins and resolvins. Prostaglandin E2 itself induces the lipoxygenase enzymes needed for SPM biosynthesis — meaning the inflammatory response carries within it the seeds of its own resolution.[1]
Tissue Regeneration Signaling: Beyond clearing inflammation, SPMs — particularly maresin 1 and protectin D1 — promote tissue repair. They stimulate planarian regeneration, accelerate wound healing, and activate stem cell programs. This positions resolution not as the mere absence of inflammation but as an active phase of tissue restoration.[4]
Clinical Evidence
Cardiovascular Disease: The REDUCE-IT trial demonstrated that icosapent ethyl (4 g/day of purified EPA ethyl ester) reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides. While the trial did not measure SPMs directly, the EPA-derived E-series resolvin pathway is a leading mechanistic explanation, particularly given that mixed EPA/DHA preparations in trials such as STRENGTH did not replicate the benefit — pointing to substrate-specific resolution biology.[5]
Resolvin Levels in Human Disease: Plasma SPM concentrations are reduced in patients with chronic inflammatory disorders including rheumatoid arthritis, atherosclerosis, and chronic periodontitis. In one investigation, peripheral artery disease patients showed a deficit in resolvin D1 and resolvin D2 relative to leukotriene B4, suggesting that failure to generate resolution mediators — not just excess pro-inflammatory signaling — contributes to chronicity.[3]
Omega-3 Supplementation and SPM Production: Human studies have shown that oral EPA and DHA supplementation increases circulating concentrations of 18-HEPE (the precursor to E-series resolvins), 17-HDHA (precursor to D-series resolvins and protectins), and 14-HDHA (precursor to maresins). This establishes a dose-dependent pharmacokinetic relationship between omega-3 intake and the substrate availability for resolution.[2]
Sepsis and Acute Lung Injury: Preclinical models show that resolvin D1 and resolvin D2 reduce mortality in murine sepsis by enhancing bacterial clearance while simultaneously dampening collateral tissue damage — a profile that distinguishes SPMs from immunosuppressive interventions, which improve one variable at the expense of the other.[4]
Safety Profile
Endogenous SPMs are generated at low nanomolar concentrations and undergo rapid enzymatic inactivation, primarily through 15-prostaglandin dehydrogenase and omega-oxidation pathways. This short half-life is a feature of physiologic signaling but a challenge for therapeutic development — most clinical exposure to SPMs is currently indirect, via omega-3 fatty acid supplementation that supplies the biosynthetic substrate.
High-dose EPA and DHA supplementation is generally well tolerated. The most common adverse effects are gastrointestinal — eructation, dyspepsia, loose stools — and a modest, dose-dependent increase in atrial fibrillation risk reported in several large randomized trials of high-dose marine omega-3s. Bleeding risk concerns at supplemental doses have not been substantiated in modern meta-analyses, including in patients on antiplatelet therapy.[5]
Synthetic SPM analogs and stable mimetics are in preclinical and early clinical development. To date, no Phase 3 trial has tested a purified resolvin or maresin in humans, and the long-term consequences of pharmacologic SPM exposure remain unknown. Patients pursuing SPM-related interventions clinically are doing so primarily through omega-3 substrate loading rather than direct mediator administration.
SPMs vs Traditional Anti-Inflammatory Approaches
NSAIDs: Non-steroidal anti-inflammatory drugs inhibit cyclooxygenase enzymes, reducing prostaglandin synthesis. But because COX-2-derived prostaglandin E2 is also required to induce the lipoxygenase enzymes that generate lipoxins and resolvins, sustained NSAID use can paradoxically impair resolution. Animal studies show that selective COX-2 inhibitors prolong inflammation by preventing the lipid mediator class switch.[1]
Corticosteroids: Glucocorticoids broadly suppress immune cell function, including the very macrophage programs needed for efferocytosis and tissue repair. They are powerful at extinguishing acute inflammatory signaling but blunt the resolution and repair phase. SPMs, by contrast, accelerate clearance of dead cells and promote regeneration without immunosuppression.
Biologics (anti-TNF, IL-6 blockade): These agents target specific cytokines that drive chronic inflammation. They are highly effective in conditions such as rheumatoid arthritis but do not restore the underlying resolution defect. SPM biology is mechanistically complementary — addressing the failure to terminate inflammation rather than the cytokines that perpetuate it.[3]
Mixed Omega-3 Supplements: The clinical divergence between purified EPA (REDUCE-IT) and EPA/DHA combinations (STRENGTH, VITAL) suggests that not all omega-3 substrate is equivalent for cardiovascular outcomes. Whether this reflects differential SPM biosynthesis, mineral oil placebo confounding, or other factors remains debated. From a resolution-pharmacology standpoint, EPA and DHA generate distinct SPM families with non-overlapping receptor targets, and combination dosing may matter for indication.[5]
The reframing is conceptually important. Inflammation has two phases — initiation and resolution — governed by separate molecular programs. Most existing pharmacology targets initiation. SPMs reveal a parallel pharmacology of resolution, and omega-3 fatty acids, viewed through this lens, are not generic anti-inflammatory nutrients but the substrate supply for an active termination pathway built into mammalian physiology.
References
- Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology.” Nature. 2014;510(7503):92-101.
- Serhan CN, Levy BD. “Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.” Journal of Clinical Investigation. 2018;128(7):2657-2669.
- Fredman G, Hellmann J, Proto JD, et al. “An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.” Nature Communications. 2016;7:12859.
- Spite M, Clària J, Serhan CN. “Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases.” Cell Metabolism. 2014;19(1):21-36.
- Bhatt DL, Steg PG, Miller M, et al. “Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.” New England Journal of Medicine. 2019;380(1):11-22.
